Shattuck Labs Q3 net loss more than doubles to $25.2 million
STTK•STTK•STTK•STTK•Shattuck Labs reported a third-quarter 2026 net loss of $25.2 million, more than double a year earlier, and $196.3 million in cash, cash equivalents and short-term investments at September 30. The company said its operations are expected to be funded into 2029.
Shattuck Labs’ third-quarter net loss more than doubled year over year to $25.2 million, while research and development expenses more than doubled to $21.6 million. The company reported $196.3 million in cash, cash equivalents and short-term investments at September 30, 2026, and said it expects its operations to be funded into 2029. Its Phase 2b SL-325 Crohn’s disease trial began, with 12-week induction data expected in the first half of 2028; a Phase 2 trial of SL-325 for hidradenitis suppurativa is expected to begin in the fourth quarter of 2026, with data anticipated in the first half of 2028.
